Similar articles

• Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.

  Tomic R, Ljungberg B, Damber JE. Tomic R, et al. Scand J Urol Nephrol Suppl. 1988;110:185-7. Scand J Urol Nephrol Suppl. 1988. PMID: 2973122 No abstract available.
• High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.

  Kjaer M, Frederiksen PL. Kjaer M, et al. Cancer Treat Rep. 1986 Mar;70(3):431-2. Cancer Treat Rep. 1986. PMID: 2937534 No abstract available.
• Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma.

  Nilsson TK, Tomic R, Ljungberg B. Nilsson TK, et al. Scand J Urol Nephrol. 1989;23(1):11-4. doi: 10.1080/00365599.1989.11690424. Scand J Urol Nephrol. 1989. PMID: 2522237
• An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.

  Robustelli della Cuna G, Zanon P, Pavesi L, Preti P, Prada GA, Decensi A. Robustelli della Cuna G, et al. Chemioterapia. 1986 Jun;5(3):164-72. Chemioterapia. 1986. PMID: 2941173 Review.
• Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

  Stockdale AD, Rostom AY. Stockdale AD, et al. Clin Pharmacokinet. 1989 Mar;16(3):129-33. doi: 10.2165/00003088-198916030-00001. Clin Pharmacokinet. 1989. PMID: 2524303 Review. No abstract available.